Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing in Economic Times on December 31, 2014 titled "Wockhardt, Cadila & Hospira voluntarily recall drugs in US." The reply is awaited. Updates
Cadila Healthcare Ltd has informed BSE that during an interaction with a media person of the Company Chairman and Managing Director was asked about healthcare concerns caused by "Congo Virus" and "Ebola Virus" and he had responded by saying that group was developing vaccines for these diseases as a part of Company's vaccine development programme. There were no investment details shared during the interaction. Abstract of interaction with press
Cadila Healthcare Ltd has informed BSE regarding "Abstract of interaction with press". Cadila Healthcare Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news appearing in DNA on December 17, 2014 titled "Cadila's US Arm recalls 63,648 bottles of benzonatate capsules."Cadila Healthcare Ltd replied stating "the recall by our US subsidiary was voluntary and a class-III type recall, which means that the use of the product is not likely to cause any adverse health consequences. There is no material impact." Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing in DNA on December 17, 2014 titled "Cadila's US Arm recalls 63,648 bottles of benzonatate capsules." The reply is awaited. Zydus launches world's first biosimilar of Adalimumab
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated December 09, 2014, titled "Zydus launches world's first biosimilar of Adalimumab". Resignation of Director
Cadila Healthcare Ltd has informed BSE that the Directors of the Company vide circular resolution approved the resignation of Shri. Apurva S. Diwanji.The resignation has been received and taken on record on December 04, 2014. Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Cadila Healthcare Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 Disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Ganesh N Nayak has submitted the disclosures under Reg.13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992 Results Press Release
Cadila Healthcare Ltd has submitted to BSE a copy of the Results Press Release for the period ended September 30, 2014.